Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12150961
APP PUB NO 20220072044A1
SERIAL NO

17524883

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NIMMUNE BIOPHARMA INC1013 MCBRYDE LANE BLACKSBURG VA 24060

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bassaganya-Riera, Josep Blacksburg, US 49 187
Hontecillas, Raquel Blacksburg, US 39 164
Leber, Andrew Blacksburg, US 21 14

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 26, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 May 26, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 26, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00